Foresite Capital Management Ii Lowers stake in Aimmune Therapeutics Inc (AIMT)

Aimmune Therapeutics Inc (AIMT) : Foresite Capital Management Ii reduced its stake in Aimmune Therapeutics Inc by 2.94% during the most recent quarter end. The investment management company now holds a total of 3,967,900 shares of Aimmune Therapeutics Inc which is valued at $51,106,552 after selling 120,000 shares in Aimmune Therapeutics Inc , the firm said in a disclosure report filed with the SEC on Aug 12, 2016.Aimmune Therapeutics Inc makes up approximately 32.40% of Foresite Capital Management Ii’s portfolio.

Other Hedge Funds, Including , Laurion Capital Management Lp sold out all of its stake in AIMT during the most recent quarter. The investment firm sold 11,000 shares of AIMT which is valued $141,680.Alliancebernstein boosted its stake in AIMT in the latest quarter, The investment management firm added 105,246 additional shares and now holds a total of 742,217 shares of Aimmune Therapeutics Inc which is valued at $9,559,755. Aimmune Therapeutics Inc makes up approx 0.01% of Alliancebernstein’s portfolio.Blackrock Institutional Trust Company N.a. boosted its stake in AIMT in the latest quarter, The investment management firm added 140,908 additional shares and now holds a total of 257,509 shares of Aimmune Therapeutics Inc which is valued at $3,316,716.Eagle Asset Management Inc boosted its stake in AIMT in the latest quarter, The investment management firm added 227,439 additional shares and now holds a total of 1,988,434 shares of Aimmune Therapeutics Inc which is valued at $22,190,923. Aimmune Therapeutics Inc makes up approx 0.15% of Eagle Asset Management Inc’s portfolio.

Aimmune Therapeutics Inc formerly Allergen Research Corporation is a United States-based clinical-stage biopharmaceutical company. The Company focuses on therapeutic approach including the development of proprietary candidates for the treatment of peanut and other food allergies. The Company’s Characterized Oral Desensitization Immunotherapy (CODIT) is a system designed to desensitize patients to food allergens using characterized biologic products defined treatment protocols and support services. Its lead product AR101 which has completed a Phase II study is designed to treat peanut allergy. The Company’s AR101 is a mixture of naturally occurring proteins and pharmaceutical-grade ingredients. Its CODIT system aims to improve upon oral immunotherapy (OIT) by precisely controlling the amount of food protein administered and establishing very gradual treatment regimens that begin with low doses of protein.

Leave a Reply

Aimmune Therapeutics Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Aimmune Therapeutics Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.